BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 25266362)

  • 1. Antibody-independent targeted quantification of TMPRSS2-ERG fusion protein products in prostate cancer.
    He J; Sun X; Shi T; Schepmoes AA; Fillmore TL; Petyuk VA; Xie F; Zhao R; Gritsenko MA; Yang F; Kitabayashi N; Chae SS; Rubin MA; Siddiqui J; Wei JT; Chinnaiyan AM; Qian WJ; Smith RD; Kagan J; Srivastava S; Rodland KD; Liu T; Camp DG
    Mol Oncol; 2014 Oct; 8(7):1169-80. PubMed ID: 25266362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analytical platform evaluation for quantification of ERG in prostate cancer using protein and mRNA detection methods.
    He J; Schepmoes AA; Shi T; Wu C; Fillmore TL; Gao Y; Smith RD; Qian WJ; Rodland KD; Liu T; Camp DG; Rastogi A; Tan SH; Yan W; Mohamed AA; Huang W; Banerjee S; Kagan J; Srivastava S; McLeod DG; Srivastava S; Petrovics G; Dobi A; Srinivasan A
    J Transl Med; 2015 Feb; 13():54. PubMed ID: 25889691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased androgen receptor gene copy number is associated with TMPRSS2-ERG rearrangement in prostatic small cell carcinoma.
    Wang L; Williamson SR; Zhang S; Huang J; Montironi R; Davison DD; Wang M; Yao JL; Lopez-Beltran A; Osunkoya AO; MacLennan GT; Baldridge LA; Du X; Cheng L
    Mol Carcinog; 2015 Sep; 54(9):900-7. PubMed ID: 24777847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of steroid and peptide hormone receptors, metabolic enzymes and EMT-related genes in prostate tumors in relation to the presence of the TMPRSS2/ERG fusion.
    Gerashchenko GV; Mevs LV; Chashchina LI; Pikul MV; Gryzodub OP; Stakhovsky EO; Kashuba VI
    Exp Oncol; 2018 Jun; 40(2):101-108. PubMed ID: 29949537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer.
    Furusato B; Gao CL; Ravindranath L; Chen Y; Cullen J; McLeod DG; Dobi A; Srivastava S; Petrovics G; Sesterhenn IA
    Mod Pathol; 2008 Feb; 21(2):67-75. PubMed ID: 18065961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retention of Interstitial Genes between
    Murphy SJ; Kosari F; Karnes RJ; Nasir A; Johnson SH; Gaitatzes AG; Smadbeck JB; Rangel LJ; Vasmatzis G; Cheville JC
    Cancer Res; 2017 Nov; 77(22):6157-6167. PubMed ID: 29127096
    [No Abstract]   [Full Text] [Related]  

  • 7. Significance of the TMPRSS2:ERG gene fusion in prostate cancer.
    Wang Z; Wang Y; Zhang J; Hu Q; Zhi F; Zhang S; Mao D; Zhang Y; Liang H
    Mol Med Rep; 2017 Oct; 16(4):5450-5458. PubMed ID: 28849022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer.
    Winnes M; Lissbrant E; Damber JE; Stenman G
    Oncol Rep; 2007 May; 17(5):1033-6. PubMed ID: 17390040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel four-color fluorescence in situ hybridization assay for the detection of TMPRSS2 and ERG rearrangements in prostate cancer.
    Qu X; Randhawa G; Friedman C; O'Hara-Larrivee S; Kroeger K; Dumpit R; True L; Vakar-Lopez F; Porter C; Vessella R; Nelson P; Fang M
    Cancer Genet; 2013; 206(1-2):1-11. PubMed ID: 23352841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cysteine-rich secretory protein-3 (CRISP3) is strongly up-regulated in prostate carcinomas with the TMPRSS2-ERG fusion gene.
    Ribeiro FR; Paulo P; Costa VL; Barros-Silva JD; Ramalho-Carvalho J; Jerónimo C; Henrique R; Lind GE; Skotheim RI; Lothe RA; Teixeira MR
    PLoS One; 2011; 6(7):e22317. PubMed ID: 21814574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TMPRSS2/ERG fusion gene expression alters chemo- and radio-responsiveness in cell culture models of androgen independent prostate cancer.
    Swanson TA; Krueger SA; Galoforo S; Thibodeau BJ; Martinez AA; Wilson GD; Marples B
    Prostate; 2011 Oct; 71(14):1548-58. PubMed ID: 21394739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States.
    Mosquera JM; Mehra R; Regan MM; Perner S; Genega EM; Bueti G; Shah RB; Gaston S; Tomlins SA; Wei JT; Kearney MC; Johnson LA; Tang JM; Chinnaiyan AM; Rubin MA; Sanda MG
    Clin Cancer Res; 2009 Jul; 15(14):4706-11. PubMed ID: 19584163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mapping Isoform Abundance and Interactome of the Endogenous TMPRSS2-ERG Fusion Protein by Orthogonal Immunoprecipitation-Mass Spectrometry Assays.
    Fu Z; Rais Y; Bismar TA; Hyndman ME; Le XC; Drabovich AP
    Mol Cell Proteomics; 2021; 20():100075. PubMed ID: 33771697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Frequency and transcript variant analysis of gene fusions between TMPRSS2 and ETS transcription factor genes in prostate cancer].
    Dai MJ; Chen LL; Zheng YB; Chen W; Tao ZH; Weng ZL; Wu XL; Li CD; Chen ZG; Chen XD; Shi SB
    Zhonghua Yi Xue Za Zhi; 2008 Mar; 88(10):669-73. PubMed ID: 18642766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Micro-RNA-204 Participates in TMPRSS2/ERG Regulation and Androgen Receptor Reprogramming in Prostate Cancer.
    Todorova K; Metodiev MV; Metodieva G; Mincheff M; Fernández N; Hayrabedyan S
    Horm Cancer; 2017 Feb; 8(1):28-48. PubMed ID: 28050800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of the TMPRSS2-ERG gene fusion in prostate cancer.
    Tomlins SA; Laxman B; Varambally S; Cao X; Yu J; Helgeson BE; Cao Q; Prensner JR; Rubin MA; Shah RB; Mehra R; Chinnaiyan AM
    Neoplasia; 2008 Feb; 10(2):177-88. PubMed ID: 18283340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
    Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J
    Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis.
    Lapointe J; Kim YH; Miller MA; Li C; Kaygusuz G; van de Rijn M; Huntsman DG; Brooks JD; Pollack JR
    Mod Pathol; 2007 Apr; 20(4):467-73. PubMed ID: 17334351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer.
    Pflueger D; Rickman DS; Sboner A; Perner S; LaFargue CJ; Svensson MA; Moss BJ; Kitabayashi N; Pan Y; de la Taille A; Kuefer R; Tewari AK; Demichelis F; Chee MS; Gerstein MB; Rubin MA
    Neoplasia; 2009 Aug; 11(8):804-11. PubMed ID: 19649210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer.
    Laxman B; Tomlins SA; Mehra R; Morris DS; Wang L; Helgeson BE; Shah RB; Rubin MA; Wei JT; Chinnaiyan AM
    Neoplasia; 2006 Oct; 8(10):885-8. PubMed ID: 17059688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.